Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Debt: 2019-2024

Historic Total Debt for Tg Therapeutics (TGTX) over the last 6 years, with Dec 2024 value amounting to $244.4 million.

  • Tg Therapeutics' Total Debt rose 0.48% to $245.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.3 million, marking a year-over-year increase of 0.48%. This contributed to the annual value of $244.4 million for FY2024, which is 144.14% up from last year.
  • Per Tg Therapeutics' latest filing, its Total Debt stood at $244.4 million for FY2024, which was up 144.14% from $100.1 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Total Debt registered a high of $244.4 million during FY2024, and its lowest value of $29.9 million during FY2020.
  • Over the past 3 years, Tg Therapeutics' median Total Debt value was $100.1 million (recorded in 2023), while the average stood at $138.6 million.
  • Data for Tg Therapeutics' Total Debt shows a peak YoY spiked of 144.14% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Tg Therapeutics' Total Debt stood at $29.9 million in 2020, then skyrocketed by 126.67% to $67.8 million in 2021, then grew by 4.98% to $71.1 million in 2022, then spiked by 40.74% to $100.1 million in 2023, then soared by 144.14% to $244.4 million in 2024.